Antibody Therapy Market Size - By Type (Monoclonal Antibodies [mAbs] {Oncology, Autoimmune Diseases, Infectious Diseases}, Antibody-drug Conjugates [ADCs]), By End-use (Hospitals, Specialty Centers) & Forecast, 2022 - 2028

Industry Overview

Antibody Therapy Market size was valued at over USD 186 billion in 2021 and is projected to witness a CAGR of 13.2% from 2022 to 2028 as new therapies and drugs have been approved for the treatment of diseases. Increasing demand for targeted drug therapies coupled with growing advancement in technology will drive the antibody therapy industry growth.
 

To get more details on this report: Request Free Sample PDF
 

To date, the Food and Drug Administration (FDA) has approved more than 100 antibody products and every year around a fifth of new drug approvals are of biologics. The presence of a healthy antibody therapy pipeline creates a high potential for the company to attain larger market revenue. Thus, a surge in the development of new antibody products due to high demand is expected to drive the antibody therapy market share.
 

Rising cancer cases across the globe are anticipated to positively influence the demand for antibodies therapy. As per the Global Cancer Observatory (GLOBOCAN) estimates, in 2020 about 19.3 million new cancer cases had been reported and around 10 million associated deaths occurred. According to World Health Organization (WHO), cancer is the first/second leading cause of death in many countries which decreases life expectancy.
 

The rising prominence of cancer and the high mortality rate have raised the demand for effective and targeted therapies like antibody therapy. Recently, antibody-based treatments are becoming more technologically advanced by targeting tumor antigens and enhancing the anti-tumor capabilities of immune cells. Moreover, high product advancement and technologies for the treatment of cancer are expected to spur the antibody therapy market growth.
 

Antibody therapy is a targeted therapeutic intervention in which a concentrated or monoclonal antibody is used to manage diseases like cancer, infectious diseases, autoimmune diseases, and others. The antibodies target the specific antigen which activate or inhibit a cascade of biological responses such as blockage of cancer growth, triggering of immune system and many others.
 

COVID-19 severely impacted the global economy including all nations by disrupting the operations of every sector, irrespective of the size. The healthcare sector felt an impact by the increasing prevalence of COVID-19 cases. While the influence of COVID-19 has been mostly negative in several areas, the antibody therapy industry gained considerable momentum due to a spike in demand for the treatment development of COVID-19.
 

Several companies commenced their R&D at a faster pace for the development of diagnostic and treatment related to COVID. The FDA and other organizations of various countries gave emergency use authorizations (EUAs) for the use of anti-SARS-CoV-2 mAb and other antibody therapy for the treatment of mild to moderate COVID-19 infection. The EUA products used during pandemic are sotrovimab, casirivimab plus imdevimab, and bamlanivimab plus etesevimab.
 

Such fast product approvals for the treatment of COVID-19 have positively impacted the antibody therapy industry growth during the pandemic. Hence, COVID-19 is projected to have a positive effect on the market of antibody therapy.
 

Rising drug approval will drive the market size during the forecast period

The government and key market players have significantly increased R&D expenditure due to the high demand for antibody therapy in the market. Governmental support for the launch of novel treatment is expected to contribute to strong market growth. In September 2021, Amgen received FDA approval for its Repatha (evolocumab) for the treatment of heterozygous familial hypercholesterolemia (HeFH) patients aged 10 years and older. This approval will benefit the patients suffering from HeFH. Also, in September 2021, Seagen Inc. and Astellas Pharma Inc. announced FDA approval of PADCEV in the U.S. PADCEV is an ADC approved therapy for patients suffering from locally advanced or metastatic urothelial cancer. Such continuous product approvals in developing and developed nations are expected to drive the market growth of antibody therapy in the future.
 

Increasing applications and development strategies will augment demand for monoclonal antibodies

To get more details on this report: Request Free Sample PDF
 

Global antibody therapy market based on type is segmented into monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs). The mAbs market is further split into oncology, autoimmune diseases, infectious diseases, and others. The mAbs segment is expected to expand at a 12.9% CAGR through 2028 due to the increasing application of mAbs for the treatment of various diseases such as cancer, infection, genetic diseases, and others. mAbs as biologic products elicit several immune-mediated reactions and responses which increases the efficiency of the therapy.
 

mAbs are synthesized using recombinant biotechnology and progress in protein engineering, recombinant DNA technology, and various other platforms for generating different types of antibodies based on novel strategies, resulting in future segment market growth of antibody therapy over forecast period.
 

Availability of advanced treatment at hospitals will drive the demand for antibody therapy

The antibody therapy market based on end-use is segmented into hospitals, specialty centers, and other end-users. In 2021, the hospitals segment held the major market share of more than 42%. An increase in the number of people opting for treatment in hospitals due to guidelines, availability, and accessibility is going to further stimulate market growth. Hospitals offer sophisticated treatment, easy availability of advanced treatment, post administration monitoring and the presence of a skilled workforce at one place. These factors are collectively driving the preference of patients for hospitals, thereby stimulating the market growth of antibody therapy over predicted timeframe.
 

Growing healthcare expenditure and rising incidence of cancer will positively impact the North America antibody therapy market size

To get more details on this report: Request Free Sample PDF
 

North America antibody therapy market held over 49.1% share in 2021 owing to the rising investment in novel antibody therapy development by key players. Consequentially, with the high demand for the targeted drugs in the region, the number of clinical trials has increased, thereby contributing to the overall growth of the market. Furthermore, sophisticated healthcare infrastructure in the region coupled with high healthcare expenditure is expected to augment the regional market growth.
 

Cancer’s rising prominence in North America creates a lucrative opportunity for the market. In the U.S. approximately 1.8 million cancer cases were diagnosed in 2020 and about 606,520 people died. As per the National Cancer Institute, the incidence rate of cancer is 442.4 per 100,000 and the mortality rate is around 158.3 per 100,000 people. Such exponential rise in cancer cases will boost the demand for cancer diagnostic and treatment.
 

New drug development and government approvals are key strategies adopted by major market players

Major market players involved in the antibody therapy industry include AbbVie Inc, Amgen, Bristol Myers Squibb, GlaxoSmithKline plc, Takeda Pharmaceuticals, Eli Lilly and Company,  F. Hoffmann-La Roche Ltd., Merck & Co, Inc, Seagen, Johnson & Johnson, Novartis AG, Regeneron Pharmaceuticals Inc., and AstraZeneca among other market players. These market players have incorporated a variety of strategic initiatives such as new product launch, acquisitions, collaborations and others that have enhanced their industry hold and helped them evolve as major industry players.
 

Some of the recent industry developments:

• In January 2022, Amgen and AstraZeneca announced the approval and availability of TEZSPIRE (tezepelumab-ekko) for the treatment of severe asthma. Such drug approval by FDA will benefit the company to expand its product portfolio in the industry and generate noteworthy revenue.
   
• In November 2020, Regeneron announced the Emergency Use Authorization (EUA) by the U.S.FDA for its antibody cocktail casirivimab and imdevimab developed for COVID-19 treatment. This approval has stimulated the revenue generation of the company and helped to acquire significant market share.
   

Antibody Therapy Market report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2022 to 2028 for the following segments:

Click here to Buy Section of this Report

By Type

• Monoclonal antibodies (mAbs)
  • Oncology
  • Autoimmune diseases
  • Infectious diseases
  • Others
• Antibody-drug conjugates (ADCs)

By End-use

• Hospitals
• Specialty Centers
• Others

The above information is provided for the following regions and countries:

By Region

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • Singapore
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East & Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Kuwait
  • Egypt